- Home
- RXST vs KROS Comparison
RXST vs KROS Comparison
Compare RXST & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXST
- KROS
- Stock Information
- Founded
- RXST 1997
- KROS 2015
- Country
- RXST United States
- KROS United States
- Employees
- RXST N/A
- KROS N/A
- Industry
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- RXST Health Care
- KROS Health Care
- Exchange
- RXST Nasdaq
- KROS Nasdaq
- Market Cap
- RXST 2.0B
- KROS 633.5M
- IPO Year
- RXST 2021
- KROS 2020
- Fundamental
- Price
- RXST $34.55
- KROS $15.92
- Analyst Decision
- RXST Strong Buy
- KROS Buy
- Analyst Count
- RXST 8
- KROS 11
- Target Price
- RXST $59.00
- KROS $68.83
- AVG Volume (30 Days)
- RXST 862.4K
- KROS 1.9M
- Earning Date
- RXST 02-26-2025
- KROS 02-26-2025
- Dividend Yield
- RXST N/A
- KROS N/A
- EPS Growth
- RXST N/A
- KROS N/A
- EPS
- RXST N/A
- KROS N/A
- Revenue
- RXST $128,293,000.00
- KROS $651,000.00
- Revenue This Year
- RXST $60.30
- KROS $224.66
- Revenue Next Year
- RXST $34.32
- KROS N/A
- P/E Ratio
- RXST N/A
- KROS N/A
- Revenue Growth
- RXST 67.52
- KROS 8037.50
- 52 Week Low
- RXST $33.03
- KROS $15.33
- 52 Week High
- RXST $66.54
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- RXST 33.96
- KROS 22.66
- Support Level
- RXST $33.03
- KROS $15.33
- Resistance Level
- RXST $35.32
- KROS $17.25
- Average True Range (ATR)
- RXST 1.61
- KROS 1.37
- MACD
- RXST 0.04
- KROS -0.48
- Stochastic Oscillator
- RXST 23.97
- KROS 10.31
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.